ALIMERA SCIENCES, INC. WARRANT TO PURCHASE SHARES OF SERIES A PREFERRED STOCKPurchase Agreement • October 2nd, 2012 • Alimera Sciences Inc • Pharmaceutical preparations • Delaware
Pursuant to the terms of that certain Securities Purchase Agreement (as may be amended or restated from time to time, the “Purchase Agreement”) dated as of July 17, 2012, among Alimera Sciences, Inc., a Delaware corporation (the “Company”), the Holder (as defined below) and certain other investors, for consideration, the receipt and sufficiency of which is hereby acknowledged, this Warrant (this “Warrant”) is issued to Palo Alto Healthcare Master Fund II, L.P., a Cayman Islands limited partnership, or its assigns (the “Holder”) by the Company. Capitalized terms not defined herein shall have the meanings set forth in the Purchase Agreement.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 2nd, 2012 • Alimera Sciences Inc • Pharmaceutical preparations • Delaware
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 2, 2012, among Palo Alto Healthcare Master Fund, L.P., a Cayman Islands limited Partnership (“PAHF”), Palo Alto Healthcare Master Fund II, L.P., a Cayman Islands limited Partnership (“PAHF II”), Micro Cap Partners, L.P., a Delaware limited partnership (“Micro Cap” and, collectively with PAHF and PAHF II, “PAI”), Sofinnova Venture Partners VIII L.P., a Delaware limited partnership (“Sofinnova”) and Growth Equity Opportunities Fund III, LLC, a Delaware limited liability company (each a “Shareholder” and collectively, the “Shareholders”) on the one hand, and Alimera Sciences, Inc., a Delaware corporation (the “Company”), on the other hand.
AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 2nd, 2012 • Alimera Sciences Inc • Pharmaceutical preparations • Delaware
This Amendment No. 1 to the Securities Purchase Agreement (the “Amendment”) is made and entered into as of September 21, 2012 (the “Effective Date”), between Alimera Sciences, Inc., a Delaware corporation (the “Company”) and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser”, and collectively, the “Purchasers”).
